The $110M upfront provides immediate cash runway and validates HUTCHMED's ATTC platform. Monitor the Phase I start in H2 2026 and any early clinical data readouts. The GSK partnership significantly de-risks development costs and adds a major pharma partner, which could drive re-rating. Watch for potential antitrust clearance as a near-term catalyst.
Price Chart
Executive Summary
HUTCHMED announced an exclusive worldwide licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC) for colorectal, pancreatic, and lung cancers. The deal includes a $110 million upfront payment and up to $1.295 billion in total milestones plus tiered royalties, with HUTCHMED retaining rights in Greater China. This is a major non-dilutive validation of HUTCHMED's ATTC platform and provides significant near-term cash, though the asset is still pre-clinical with Phase I starting H2 2026.
Key Facts
- HUTCHMED licensed HMPL-A830 (KRAS-EGFR ATTC) to GSK for ex-China rights.
- Upfront payment of $110 million; total potential milestones up to $1.295 billion plus tiered royalties.
- HUTCHMED retains full rights in Mainland China, Hong Kong, Macau, and Taiwan.
- GSK gets right of first negotiation on one earlier-stage ATTC candidate.
- Phase I clinical trial expected to start H2 2026 (NCT07718581).
- BofA Securities acted as exclusive financial advisor to HUTCHMED.
Financial Impact
$110 million upfront + up to $1.185 billion in milestones + tiered royalties on net sales
Risk Factors
- Deal subject to customary closing conditions including antitrust regulatory reviews.
- HMPL-A830 is pre-clinical; Phase I has not yet started and clinical data may not replicate preclinical results.
- Milestone payments are contingent on development and regulatory success, which is uncertain.
- GSK has a right of first negotiation on one earlier-stage ATTC candidate, potentially limiting future partnering optionality.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000057 |
| Document: hcm-20260903x6k.htm | 0001648257-26-000057 |
| Document: 0001648257-26-000057-index-headers.html | 0001648257-26-000057 |
| Document: 0001648257-26-000057-index.html | 0001648257-26-000057 |
| Document: 0001648257-26-000057.txt | 0001648257-26-000057 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access